Top Companies in the Bispecific T-cell Engagers Market & Their Offerings
| Companies | Headquarters | Offerings |
| Amgen | California, U.S. | Develops BiTE-based immunotherapies for blood cancers and advanced oncology treatments. |
| Roche / Genentech | California, U.S. | Focuses on bispecific antibody therapies for solid tumors and hematologic malignancies |
| Regeneron Pharmaceuticals | New York, U.S. | Develops engineered bispecific antibodies for cancer immunotherapy and immune-related disorders. |
| Genmab | Copenhagen, Denmark | Offers next-generation bispecific antibody platforms for targeted oncology therapies. |
| MacroGenics | Maryland, U.S. | Specializes in DART-based bispecific antibody technologies for cancer treatment research. |
| Xencor | California, U.S. | Provides engineered bispecific antibody platforms for oncology and autoimmune disease therapies. |
| Pfizerâ | New York, U.S. | Expands immuno-oncology pipelines with bispecific antibody therapies targeting multiple cancers. |
What are the Recent Developments in the Bispecific T-cell Engagers Market? 
- In January 2026, Bristol Myers Squibb partnered with Janux Therapeutics to develop an advanced tumor-activated T-cell engager therapy for solid tumors. Under the agreement, Janux will use its proprietary platform technology during preclinical development, while Bristol Myers Squibb will manage clinical trials and global commercialization activities for the therapy.
- In March 2026, Kali Therapeutics entered an exclusive licensing agreement with Sanofi for KT501, a next-generation tri-specific T-cell engager designed for B-cell-related autoimmune diseases. Through this agreement, Sanofi obtained global rights to develop and commercialize the therapy.
Supply Chain Analysis
R&D
- Research and development activities in the bispecific T-cell engagers (TCEs) market are mainly focused on improving antibody design to enhance the ability of T-cells to recognize and attack cancer cells more effectively. Companies are developing advanced therapies that target CD3 and tumor-associated antigens to increase treatment precision and reduce side effects.
- Key players: Amgen, Roche, Pfizer, and Johnson & Johnson.
Clinical Trials
- Clinical trials for bispecific T-cell engagers (TCEs) are advancing rapidly, with a major focus on treating blood cancers while expanding research into solid tumors. Increasing FDA approvals and positive clinical outcomes are accelerating the adoption of these targeted immunotherapies worldwide.
- Key Players: Genmab, AbbVie, Regeneron Pharmaceuticals, and Gilead Sciences.
Patient Support and Services
- Patient support services in the bispecific T-cell engagers (BiTEs) market are focused on helping patients manage treatment-related side effects such as cytokine release syndrome (CRS) and neurological complications during immunotherapy. Companies are also improving monitoring programs, patient assistance, and personalized care to enhance treatment safety and quality of life.
- Key players: Bristol Myers Squibb, AstraZeneca, Novartis, and Merck & Co.
Market Growth
The global bispecific T-cell engagers market size was estimated at USD 8.94 billion in 2025 and is predicted to increase from USD 10.61 billion in 2026 to approximately USD 49.73 billion by 2035, expanding at a CAGR of 18.72% from 2026 to 2035.
Keypoints
- Company Overview
- Locations Subsidiaries/Geographic reach
- Key Executives
- Company Financials
- Patents registered
- SWOT Analysis
- Applications Catered
- Strategic collaborations
- Recent Developments
- Competitive Benchmarking